Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Complete Inactivation of Blood Borne Pathogen Trypanosoma cruzi in Stored Human Platelet Concentrates and Plasma Treated With 405 nm Violet-Blue Light

Journal Article · · Frontiers in Medicine
 [1];  [2];  [2];  [3];  [4];  [4];  [4];  [4];  [4];  [5];  [6];  [7];  [3]
  1. U.S. Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Biologics Evaluation and Research. Office of Blood Research and Review. Lab. of Cellular Hematology; OSTI
  2. U.S. Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Biologics Evaluation and Research. Office of Blood Research and Review. Lab. of Emerging Pathogens
  3. U.S. Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Biologics Evaluation and Research. Office of Blood Research and Review. Lab. of Cellular Hematology
  4. Univ. of Strathclyde, Glasgow, Scotland (United Kingdom). Dept. of Electronic and Electrical Engineering. The Robertson Trust Lab. for Electronic Sterilization Technologies
  5. Univ. of Strathclyde, Glasgow, Scotland (United Kingdom). Dept. of Electronic and Electrical Engineering. The Robertson Trust Lab. for Electronic Sterilization Technologies; Univ. of Strathclyde, Glasgow, Scotland (United Kingdom). Dept. of Biomedical Engineering
  6. Canary, Inc., Acton, MA (United States)
  7. U.S. Food and Drug Administration (FDA), Silver Spring, MD (United States). Center for Biologics Evaluation and Research. Office of Blood Research and Review. Lab. of Emerging Pathogens
+ Show Author Affiliations
The introduction of pathogen reduction technologies (PRTs) to inactivate bacteria, viruses and parasites in donated blood components stored for transfusion adds to the existing arsenal toward reducing the risk of transfusion-transmitted infectious diseases (TTIDs). We have previously demonstrated that 405 nm violet-blue light effectively reduces blood-borne bacteria in stored human plasma and platelet concentrates. In this report, we investigated the microbicidal effect of 405 nm light on one important bloodborne parasite Trypanosoma cruzi that causes Chagas disease in humans. Our results demonstrated that a light irradiance at 15 mWcm-2 for 5 h, equivalent to 270 Jcm-2, effectively inactivated T. cruzi by over 9.0 Log10, in plasma and platelets that were evaluated by a MK2 cell infectivity assay. Giemsa stained T. cruzi infected MK2 cells showed that the light-treated parasites in plasma and platelets were deficient in infecting MK2 cells and did not differentiate further into intracellular amastigotes unlike the untreated parasites. The light-treated and untreated parasite samples were then evaluated for any residual infectivity by injecting the treated parasites into Swiss Webster mice, which did not develop infection even after the animals were immunosuppressed, further demonstrating that the light treatment was completely effective for inactivation of the parasite; the light-treated platelets had similar in vitro metabolic and biochemical indices to that of untreated platelets. Overall, these results provide a proof of concept toward developing 405 nm light treatment as a pathogen reduction technology (PRT) to enhance the safety of stored human plasma and platelet concentrates from bloodborne T. cruzi, which causes Chagas disease.
Research Organization:
Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
Sponsoring Organization:
USDOE Office of Science (SC)
Grant/Contract Number:
SC0014664
OSTI ID:
1817079
Journal Information:
Frontiers in Medicine, Journal Name: Frontiers in Medicine Vol. 7; ISSN 2296-858X
Publisher:
Frontiers Media S.A.Copyright Statement
Country of Publication:
United States
Language:
English

References (42)

New Proof-of-Concept in Viral Inactivation: Virucidal Efficacy of 405 nm Light Against Feline Calicivirus as a Model for Norovirus Decontamination journal December 2016
Trypanosoma cruzi genetic diversity: Something new for something known about Chagas disease manifestations, serodiagnosis and drug sensitivity journal August 2018
Fundamentals of the psoralen-based Helinx[trade ] technology for inactivation of infectious pathogens and leukocytes in platelets and plasma journal October 2001
Role of Lactate in Platelet Storage Lesion journal October 1993
Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates journal June 2005
In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage journal April 2007
Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) journal May 2019
Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV journal February 2003
P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates journal October 2000
Increased mortality attributed to Chagas disease: a systematic review and meta-analysis journal January 2016
Intracellular parasite killing induced by electron carriers. II. Correlation between parasite killing and the induction of oxidative events in macrophages journal September 1984
Fundamentals of the psoralen-based Helinx™ technology for inactivation of infectious pathogens and leukocytes in platelets and plasma journal October 2001
Comparison of collagen versus adenosine diphosphate in detecting antiplatelet effect in patients with coronary artery disease journal September 2009
Lethal effects of high-intensity violet 405-nm light on Saccharomyces cerevisiae, Candida albicans, and on dormant and germinating spores of Aspergillus niger journal July 2013
Trypanosoma cruzi infection in transfusion medicine journal July 2019
Cytotoxic responses to 405nm light exposure in mammalian and bacterial cells: Involvement of reactive oxygen species journal June 2016
Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light journal October 2007
Photodynamic therapy: a new antimicrobial approach to infectious disease? journal January 2004
Platelet annexin V: the ins and outs journal January 2000
Autophagy: A necessary process during the Trypanosoma cruzi life-cycle journal November 2018
Factors Influencing Changes in pH during Storage of Platelet Concentrates at 20-24°C journal January 1982
Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission (CME): T. cruzi INFECTION IN NORTH AMERICA AND SPAIN journal February 2012
Sporicidal Effects of High-Intensity 405 nm Visible Light on Endospore-Forming Bacteria journal August 2012
Evaluation of the effectiveness of a pathogen inactivation technology against clinically relevant transfusion-transmitted bacterial strains: EFFICIENCY OF PATHOGEN INACTIVATION journal May 2015
Addressing the risk of bacterial contamination in platelets: a hospital economic perspective journal July 2017
Toward universal pathogen reduction of the blood supply (Conference Report, p. 3002) journal May 2019
Trypanosoma cruzi Inactivation in Human Platelet Concentrates and Plasma by a Psoralen (Amotosalen HCl) and Long-Wavelength UV journal February 2003
Inactivation of Bacterial Pathogens following Exposure to Light from a 405-Nanometer Light-Emitting Diode Array journal April 2009
Trypanosoma cruzi and Chagas' Disease in the United States journal October 2011
A New Proof of Concept in Bacterial Reduction: Antimicrobial Action of Violet-Blue Light (405 nm) in Ex Vivo Stored Plasma journal September 2016
Noninvasive pH Monitoring in Platelet Concentrates journal January 2013
P-Selectin Expression on Platelets Determines Size and Stability of Platelet Aggregates journal October 2000
Trypanosoma cruzi infection associated with atypical clinical manifestation during the acute phase of the Chagas disease journal October 2019
Fexinidazole: A Potential New Drug Candidate for Chagas Disease journal November 2012
Aptamer Based, Non-PCR, Non-Serological Detection of Chagas Disease Biomarkers in Trypanosoma cruzi Infected Mice journal January 2014
Aptamer-Based Detection of Disease Biomarkers in Mouse Models for Chagas Drug Discovery journal January 2015
Non-ionizing 405 nm Light as a Potential Bactericidal Technology for Platelet Safety: Evaluation of in vitro Bacterial Inactivation and in vivo Platelet Recovery in Severe Combined Immunodeficient Mice journal January 2020
Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin journal September 2017
Evaluating the Potential for Resistance Development to Antimicrobial Blue Light (at 405 nm) in Gram-Negative Bacteria: In vitro and in vivo Studies journal October 2018
IL-10 Limits Parasite Burden and Protects against Fatal Myocarditis in a Mouse Model of Trypanosoma cruzi Infection journal December 2011
What Do We Know About Chagas Disease in the United States? journal December 2016
Trypanosoma cruzi infection associated with atypical clinical manifestation during the acute phase of the Chagas disease collection January 2019

Similar Records

Related Subjects

405 nm light
59 BASIC BIOLOGICAL SCIENCES
Trypanosoma cruzi
parasite
pathogen-reduction technologies
plasma
platelets